Strategic partner Thermo Fisher Scientific was among the participants in a series B round for the diagnostics technology producer.

China-based medical diagnostics technology provider WuXi Diagnostics closed a $150m series B round yesterday featuring scientific instrument producer Thermo Fisher Scientific.

ABC International Holdings, a subsidiary of financial services firm Agricultural Bank of China, also took part in the round, as did CCBI Tech Venture, a vehicle for financial services firm China Construction Bank.

The round was filled out by healthcare investment firm Shiyu Capital, healthcare fund Sunland Capital and private equity firm YF Capital, while investment bank CEC Capital was the financial adviser.

WuXi Diagnostics has developed a technology platform that utilises big data and artificial intelligence algorithms to create diagnostics products or services or help customers accelerate their research and development activities.

The company had already formed a collaboration agreement with Thermo Fisher and medical research and care provider Mayo Clinic that focuses on covid-19. It has not revealed details of earlier funding.

Gianluca Pettiti, Thermo Fisher’s senior…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.